| Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia EM Stein, CD DiNardo, DA Pollyea, AT Fathi, GJ Roboz, JK Altman, ... Blood, The Journal of the American Society of Hematology 130 (6), 722-731, 2017 | 1450 | 2017 |
| Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML CD DiNardo, EM Stein, S de Botton, GJ Roboz, JK Altman, AS Mims, ... New England Journal of Medicine 378 (25), 2386-2398, 2018 | 1344 | 2018 |
| Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation F Wang, J Travins, B DeLaBarre, V Penard-Lacronique, S Schalm, ... Science 340 (6132), 622-626, 2013 | 935 | 2013 |
| Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA) C Preudhomme, C Sagot, N Boissel, JM Cayuela, I Tigaud, S de Botton, ... Blood, The Journal of the American Society of Hematology 100 (8), 2717-2723, 2002 | 618 | 2002 |
| Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine R Itzykson, S Thépot, B Quesnel, F Dreyfus, O Beyne-Rauzy, P Turlure, ... Blood, The Journal of the American Society of Hematology 117 (2), 403-411, 2011 | 456 | 2011 |
| Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) N Boissel, H Leroy, B Brethon, N Philippe, S De Botton, A Auvrignon, ... Leukemia 20 (6), 965-970, 2006 | 453 | 2006 |
| Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia S De Botton, H Dombret, M Sanz, JS Miguel, D Caillot, R Zittoun, ... Blood, The Journal of the American Society of Hematology 92 (8), 2712-2718, 1998 | 432 | 1998 |
| Platelet formation is the consequence of caspase activation within megakaryocytes S De Botton, S Sabri, E Daugas, Y Zermati, JE Guidotti, O Hermine, ... Blood, The Journal of the American Society of Hematology 100 (4), 1310-1317, 2002 | 426 | 2002 |
| AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations K Yen, J Travins, F Wang, MD David, E Artin, K Straley, A Padyana, ... Cancer discovery 7 (5), 478-493, 2017 | 412 | 2017 |
| Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers J Popovici-Muller, RM Lemieux, E Artin, JO Saunders, FG Salituro, ... ACS medicinal chemistry letters 9 (4), 300-305, 2018 | 377 | 2018 |
| Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response MD Amatangelo, L Quek, A Shih, EM Stein, M Roshal, MD David, ... Blood, The Journal of the American Society of Hematology 130 (6), 732-741, 2017 | 370 | 2017 |
| Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib EM Stein, CD DiNardo, AT Fathi, DA Pollyea, RM Stone, JK Altman, ... Blood, The Journal of the American Society of Hematology 133 (7), 676-687, 2019 | 352 | 2019 |
| Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience L Ades, A Guerci, E Raffoux, M Sanz, P Chevallier, S Lapusan, C Recher, ... Blood, The Journal of the American Society of Hematology 115 (9), 1690-1696, 2010 | 347 | 2010 |
| Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia GJ Roboz, CD DiNardo, EM Stein, S de Botton, AS Mims, GT Prince, ... Blood, The Journal of the American Society of Hematology 135 (7), 463-471, 2020 | 317 | 2020 |
| High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group AL Taksin, O Legrand, E Raffoux, T De Revel, X Thomas, N Contentin, ... Leukemia 21 (1), 66-71, 2007 | 312 | 2007 |
| Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype N Boissel, A Renneville, V Biggio, N Philippe, X Thomas, JM Cayuela, ... Blood 106 (10), 3618-3620, 2005 | 294 | 2005 |
| Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes F Damm, O Kosmider, V Gelsi-Boyer, A Renneville, N Carbuccia, ... Blood, The Journal of the American Society of Hematology 119 (14), 3211-3218, 2012 | 291 | 2012 |
| TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia O Kosmider, V Gelsi-Boyer, M Ciudad, C Racoeur, V Jooste, N Vey, ... Haematologica 94 (12), 1676, 2009 | 282 | 2009 |
| Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation … M Balsat, A Renneville, X Thomas, S De Botton, D Caillot, A Marceau, ... Journal of Clinical Oncology 35 (2), 185-193, 2017 | 277 | 2017 |
| Ecto‐calreticulin in immunogenic chemotherapy M Obeid, A Tesniere, T Panaretakis, R Tufi, N Joza, P Van Endert, ... Immunological reviews 220 (1), 22-34, 2007 | 252 | 2007 |
